Focused On-demand Library for Ribosomal protein S6 kinase alpha-3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P51812

UPID:

KS6A3_HUMAN

Alternative names:

90 kDa ribosomal protein S6 kinase 3; Insulin-stimulated protein kinase 1; MAP kinase-activated protein kinase 1b; Ribosomal S6 kinase 2; pp90RSK2

Alternative UPACC:

P51812; B2R9V4; Q4VAP3; Q59H26; Q5JPK8; Q7Z3Z7

Background:

Ribosomal protein S6 kinase alpha-3, also known as 90 kDa ribosomal protein S6 kinase 3, plays a pivotal role in cellular processes such as proliferation, survival, and differentiation. It acts downstream of ERK signaling, mediating activation of transcription factors and regulating translation through phosphorylation. This protein is essential for EGF-stimulated phosphorylation, contributing to the transcriptional activation of immediate-early genes.

Therapeutic significance:

Linked to Coffin-Lowry syndrome and Intellectual developmental disorder, X-linked 19, Ribosomal protein S6 kinase alpha-3's involvement in these diseases highlights its potential as a therapeutic target. Understanding its role could open doors to novel therapeutic strategies for these genetic disorders.